Vexev announced today that it completed enrollment in a clinical trial evaluating its semi-autonomous ultrasound scanning technology.
The CANSCAN trial evaluates the VxWave ultrasound imaging system for arteriovenous (AV) fistula mapping in dialysis clinics. It enrolled 120 patients with chronic kidney disease to evaluate the semi-autonomous ultrasound platform. Vexev reached the enrollment milestone with leading U.S. dialysis provider U.S. Renal Care.
Dr. Varshi Broumand, an interventional nephrologist at South Texas Renal Care Group, serves as CANSCAN study principal investigator. Broumand said in a news release that the system could allow for vascular mapping within a dialysis facility. This could enable a more efficient way to obtain a permanent vascular access point.
“The VxWave ultrasound system may remove one of the biggest hurdles in the creation of vascular access,” Broumand said. “Performing the ultrasound scans during the clinic visit would make AV fistula mapping more convenient and timely and potentially avoid sending patients to additional imaging appointments.”
Australia-based Vexev designed VxWave, a robotic tomographic ultrasound system, specifically for upper limb vascular imaging. It integrates advanced robotics, machine learning and ultrasound signal processing. This combination creates a 3D vascular model and detailed report to deliver insights into vascular access points at the point of care.
“Validating this concept is the first step toward a future where intelligent machines can perform high-precision medical imaging without a human hand on the probe,” said Dr. Shannon Thomas, MD, chief medical officer, Vexev. “The potential for a robotic system guided by AI, delivering real clinical value – it’s not science fiction anymore. The real excitement begins when this can change lives, not just lab results. This is a huge step forward in our mission to improve the lives of millions of people worldwide living with end-stage kidney disease.”
